Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study

Peer Review reports

Original Submission
4 Dec 2019	Submitted	Original manuscript
8 Jan 2020	Reviewed	Reviewer Report - Kirsty Loudon
14 Feb 2020	Author responded	Author comments - Mototsugu Shimokawa
27 Feb 2020	Author responded	Author comments - Mototsugu Shimokawa
Resubmission - Version 2
14 Feb 2020	Submitted	Manuscript version 2
Publishing
2 Mar 2020	Editorially accepted
30 Mar 2020	Article published	10.1186/s13063-020-4221-7

Back to article page